Background: The purpose of this study was to define and characterize the thyroid tumor-draining
ment is not always curative, and persistent or recurrent disease occurs in up to 30% of patients. 3 The most common site for PTC metastasis and recurrent disease is the locoregional lymph nodes. 3 Although PTC lymph node metastasis is associated clinically with both a higher risk for disease recurrence and disease-specific mortality, the mechanisms underlying lymphatic dissemination of tumor cells remain elusive. [3] [4] [5] BRAF V600E mutation, which constitutively activates the mitogenactivated protein kinases -extracellular signal-regulated kinases pathway, is the most common genetic alteration in thyroid cancer and occurs in 44% of PTC and in 24% of PTC-derived poorly differentiated thyroid carcinoma or anaplastic thyroid carcinoma (ATC) cases. [6] [7] [8] In addition to the BRAF V600E mutation, ATC also frequently harbors one or more genetic alterations in the phosphatidylinositol-4,5-bisphosphate 3-kinase -protein kinase B pathway (eg, PIK3CA, AKT1, and PTEN). 9, 10 ATC is one of the most lethal types of cancer, with a median survival of just 5 months. 11 Although metastasis is observed in 10%-20% of cases, most patients with ATC die because of locally invasive disease, which is generally refractory to conventional treatment modalities (ie, radiation and chemotherapy). 11 The lack of successful treatment options for advanced thyroid cancer underscores the need for novel therapeutic strategies, as well as in vivo models that can help predict their clinical utility. In the past, in vivo models were developed by injecting human thyroid cancer cell
Head & Neck. 2017;39:1639-1646. wileyonlinelibrary.com/journal/hed lines into immunodeficient mouse strains. 2, 7, 12 Immunodeficient models, however, fail to mimic the natural tumor microenvironment, because they do not evoke protective immune responses or tumorpromoting inflammation. 13 For this reason, genetically engineered strains have been developed to study tumors that arise in situ in immunocompetent hosts. 2, 7, 12 In order to rapidly induce tumor development, orthotopic injection of tumor cell lines derived from genetically engineered mice have also been used. 2, 7, 12 Although such models are practical for defining the underlying molecular mechanisms of tumor development, the rapid progression of disease does not allow for a step-wise analysis of later events, such as lymph node metastasis. All surgical procedures were performed with the mice under general anesthesia with 2.5% isoflurane followed by immediate euthanasia.
Euthanasia was achieved by 100% carbon dioxide insufflation, followed by cervical dislocation.
| Lymph node mapping
We used these models as a first step to examine the involvement of the lymphatic system in dissemination of PTC. 
| Tissue preparation and histology
At necropsy, the primary tumor was resected en bloc with the respiratory system for processing and analysis. The neck and lung tissue specimens were fixed in 10% formalin-buffered acetate overnight, dehydrated, and embedded in paraffin. The embedded specimens were cut into 5-lm serial sections, stained with hematoxylin-eosin, and reviewed by a high-volume thyroid pathologist (N.M.).
| Subcapsular sinus width
The width (lm) of the marginal or subcapsular sinus (SCS) was measured in hematoxylin-eosin section images at 340-3200 magnification using ImageJ (National Institutes of Health, Bethesda, MD). Statistical analysis was performed using GraphPad Prism 7 software (La Jolla, CA).
Differences between groups were assessed by paired Student's t test.
All data were presented as the mean 6 SD, and P values of .05 were considered statistically significant.
| R E S U L T S 3.1 | Primary tumor
Braf V600E mice were significantly runted compared with their WT littermates, consistent with previous reports because of hypothyroidism in Braf V600 animals. 15 Histologic examination of thyroid tumors obtained 
| Lymph node mapping
Accurate identification of murine lymph nodes (<2 mm) is challenging because of their small size (<2 mm). Methylene blue and other dyes, which preferentially drain via the lymphatic system, have been used in the past to distinguish lymph nodes from the surrounding fat and connective tissue. 21 To date, however, most descriptions of blue-dye injection techniques in the mouse have focused on the hindfoot and lateral tail base. 22, 23 The locoregional lymph nodes that are responsible for draining the thyroid gland are poorly defined. Therefore, we sought to identify the lymph nodes that drain the thyroid in the mouse and determine whether this technique could be used to identify and isolate tumor-draining lymph nodes.
To expose the thyroid gland, a 1.0-cm longitudinal midline cervical incision was made in the anterior neck. The salivary glands were retracted laterally, and the underlying superficial strap muscles were then elevated away from midline, revealing the trachea and thyroid lobes ( ship is consistent with previous reports and is likely a result of the poorly connected lymphatic vasculature that connects the right and left lymphatic drainage systems in the mouse. 22 In order to demonstrate the ipsilateral axillary lymph nodes, injection at the mouse footpad had to be performed while the mouse was still alive.
| Tumor-reactive lymphadenopathy
Although no tumors demonstrated lymphatic or distant metastasis, the deep cervical lymph nodes in the Braf Figure 3I ). These findings indicate that PTC promotes expansion of lymphatic sinuses in the locoregional lymph nodes, and these effects are restricted to the tumor-draining lymph nodes, as the nondraining lymph nodes in tumor-bearing mice showed normal lymphatic sinuses ( Figure 3D) . Finally, the size of the lymph nodes and the SCSs were irrespective of age differences. No evidence of lung metastases was found in any of the animals.
| DISCUSSION

| Nodal mapping
Although the anatomy of murine lymph nodes has been described previously, detailed descriptions of the cervical lymph nodes and drainage patterns of the thyroid gland are notably absent. In particular, 
| Tumor-reactive lymphadenopathy
In the past, lymph node metastasis has been thought of as a relatively passive process, in which detached tumor cells drain via preexisting lymphatic vasculature to locoregional lymph nodes. 24, 25 However, recent studies have demonstrated that tumor dissemination is a highly regulated process that is mediated by a complex array of molecular signals. 26, 27 For example, vascular endothelial growth factor C (VEGF-C) and vascular endothelial growth factor D (VEGF-D), which bind to and stimulate vascular endothelial growth factor 3 (VEGF-3) expressed on the lymphatic endothelium, are potent inducers of lymphatic endothelial proliferation and vessel enlargement. 28 In both human and animal models, the expression of VEGF-C is significantly correlated with lymph node metastasis in a number of tumor types (eg, thyroid, 29 prostate, 30 gastric, 31 colorectal, 32 esophageal, 33 lung, 34 and breast 35 ). 36 The PTC tumor cells express VEGF-3, the major receptor for VEGF-C, and is hypothesized to benefit from VEGF-C autocrine signaling. 26, 36 Features of tumor-reactive lymphadenopathy include increased lymph flow, dilated lymphatic sinuses, and reorganization of the lymphatic channels. 28, 37 Importantly, alterations in the lymphatic architecture arise even before tumor cells reach the draining lymph nodes, indicating that the primary tumor can induce these alterations at a distance. 28, 37, 38 In a study involving implanted melanoma cells in syngeneic C57B1/6 mice, lymph node lymphangiogenesis began before melanoma cells reached the draining lymph nodes. 37 Interestingly, the primary footpad tumors, which were infiltrated primarily by macrophages and other leukocytes, showed no lymphatic or blood vessel growth. In contrast, the tumor-draining popliteal lymph nodes, which were infiltrated primarily by lymphocytes, featured enhanced lymphatic flow and enlarged lymphatic sinuses. 37 These findings indicate that macrophage infiltration of the footpad tumor was not sufficient to induce lymph node lymphangiogenesis; in contrast, B-cell accumulation of B-lymphocytes within the draining lymph nodes is required to increase lymph flow and for expansion of the lymphatic sinuses in response to tumor growth. 37 Based on their observations, the authors concluded that B-lymphocytes mediate the tumor-reactive changes, as these alterations were not observed in mice deficient for B cells. 37 In our study, the width of the SCS in the deep cervical lymph nodes of WT animals was, on average, <15 lm ( Figure 3D,F) . Notably, this is approximately the same diameter as a circulating tumor cell. In contrast, the SCS of the deep cervical lymph nodes that were draining PTC tumors were 3 to 5 times larger ( Figure 3E,F) . Size restriction may represent a physical barrier that prevents a tumor cell or a cluster of tumor cells from entering the draining lymph nodes. Moreover, dilation of the SCS, which is lined by endothelial cells, is likely a prerequisite for tumor cell entry into the draining lymph nodes. 39 As mentioned previously, lymph node mapping reports from various murine strains are not always consistent, and not all lymph nodes have been identified in various murine strains. 19, 20, 37 It is possible that observed differences in lymph node size and structure are because of genetic differences rather than tumor drainage patterns. To test this possibility, we identified and collected the popliteal lymph nodes from thyroid tumor-bearing BrafV600E/PtenHet/TPO-Cre mice and their WT littermates. Of note, popliteal lymph nodes have been previously
shown to have tumor-specific reactive changes in an implanted melanoma model. 37 Similarly, in our study, no differences in popliteal lymph node architecture and/or immune infiltrate was observed between the tumor-bearing and WT animals ( Figure 3G,H) , indicating the observed changes in the cervical, tumor-draining lymph nodes are indeed a specific reaction to the tumor and not because of genetic differences.
| C O NC LU S I O N
The increasing incidence of thyroid cancer combined with the lack of treatment options for those patients with dedifferentiated, invasive, or metastatic disease makes genetically engineered mouse models invaluable for the development of effective treatment strategies. Our finding that PTC induces increased flow through the tumor-draining lymph nodes and enlargement of the lymphatic sinuses suggests that these alterations may actively promote lymphatic metastasis of tumor cells to regional lymph nodes. Examination of additional murine and human cancers should determine whether these alterations are a feature of thyroid cancers (eg, follicular thyroid cancer) in general or if these alterations are predictive of those cancers that metastasize specifically via the lymphatics.
